A Multi-Center Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With MEDI4736, in Subjects With Relapsed or Refractory Solid Tumors

Trial Profile

A Multi-Center Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With MEDI4736, in Subjects With Relapsed or Refractory Solid Tumors

Completed
Phase of Trial: Phase I/II

Latest Information Update: 14 Sep 2017

At a glance

  • Drugs Durvalumab (Primary) ; Ibrutinib
  • Indications Advanced breast cancer; Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Pharmacyclics
  • Most Recent Events

    • 05 Sep 2017 Status changed from active, no longer recruiting to completed.
    • 03 Jan 2017 Status changed from recruiting to active, no longer recruiting.
    • 02 Sep 2016 Planned End Date changed from 1 Jun 2019 to 1 Jun 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top